130 related articles for article (PubMed ID: 11252615)
1. A Bayesian decision approach for sample size determination in phase II trials.
Leung DH; Wang YG
Biometrics; 2001 Mar; 57(1):309-12. PubMed ID: 11252615
[TBL] [Abstract][Full Text] [Related]
2. Sample size determination for phase II clinical trials based on Bayesian decision theory.
Stallard N
Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
[TBL] [Abstract][Full Text] [Related]
3. Decision theoretic designs for phase II clinical trials with multiple outcomes.
Stallard N; Thall PF; Whitehead J
Biometrics; 1999 Sep; 55(3):971-7. PubMed ID: 11315037
[TBL] [Abstract][Full Text] [Related]
4. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
Zhao L; Woodworth G
Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
[TBL] [Abstract][Full Text] [Related]
5. Approximately optimal designs for phase II clinical studies.
Stallard N
J Biopharm Stat; 1998 Jul; 8(3):469-87. PubMed ID: 9741860
[TBL] [Abstract][Full Text] [Related]
6. Decision-theoretic designs for pre-phase II screening trials in oncology.
Stallard N; Thall PF
Biometrics; 2001 Dec; 57(4):1089-95. PubMed ID: 11764248
[TBL] [Abstract][Full Text] [Related]
7. Sample sizes for phase II clinical trials derived from Bayesian decision theory.
Brunier HC; Whitehead J
Stat Med; 1994 Dec 15-30; 13(23-24):2493-502. PubMed ID: 7701149
[TBL] [Abstract][Full Text] [Related]
8. Designing a series of decision-theoretic phase II trials in a small population.
Hee SW; Stallard N
Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
[TBL] [Abstract][Full Text] [Related]
9. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
[TBL] [Abstract][Full Text] [Related]
10. Decision-theoretic designs for phase II clinical trials allowing for competing studies.
Stallard N
Biometrics; 2003 Jun; 59(2):402-9. PubMed ID: 12926725
[TBL] [Abstract][Full Text] [Related]
11. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
12. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
13. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
Sambucini V
J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
[TBL] [Abstract][Full Text] [Related]
14. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints.
Guo B; Liu S
Biom J; 2020 Mar; 62(2):339-349. PubMed ID: 31402481
[TBL] [Abstract][Full Text] [Related]
15. Optimal choice of the number of treatments to be included in a clinical trial.
Stallard N; Posch M; Friede T; Koenig F; Brannath W
Stat Med; 2009 Apr; 28(9):1321-38. PubMed ID: 19243083
[TBL] [Abstract][Full Text] [Related]
16. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
Kikuchi T; Gittins J
Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
[TBL] [Abstract][Full Text] [Related]
17. An adaptive two-stage design with treatment selection using the conditional error function approach.
Wang J
Biom J; 2006 Aug; 48(4):679-89. PubMed ID: 16972720
[TBL] [Abstract][Full Text] [Related]
18. Bayesian optimal design for phase II screening trials.
Ding M; Rosner GL; Müller P
Biometrics; 2008 Sep; 64(3):886-894. PubMed ID: 18162113
[TBL] [Abstract][Full Text] [Related]
19. Optimal sample size determinations from an industry perspective based on the expected value of information.
Willan AR
Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
[TBL] [Abstract][Full Text] [Related]
20. Effect of a misspecification of response rates on type I and type II errors, in a phase II Simon design.
Baey C; Le Deley MC
Eur J Cancer; 2011 Jul; 47(11):1647-52. PubMed ID: 21493059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
